Inovio Pharmaceuticals

INO · NASDAQ

$1.01+$0.01 (+1.00%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $1.00

INO analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 4 analysts

Average $3.23 (+219.8% upside)

Low: $2.53
Now: $1.01
High: $4.20

Upgrades and downgrades

The latest rating actions, newest first

INO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jefferies	Aug 13, 2026	Upgrade	Hold → Buy	$1.80 → $3.00	46%
Piper Sandler	Aug 3, 2026	Maintains	Overweight	$6.00 → $4.00	40%
HC Wainwright & Co.	Jun 1, 2026	Maintains	Neutral	$3.00 → $2.50	43%
Piper Sandler	Nov 14, 2025	Maintains	Overweight	$5.00 → $6.00	40%

The case for and against

Updated Oct 31, 2025

Bull case

Inovio Pharmaceuticals Inc. demonstrates a positive outlook due to its diversified clinical pipeline in immuno-oncology, which has the potential to unlock significant medium-term value. The company is making progress with key assets such as INO-3107 and INO-5401 while also working towards the rejuvenation of VGX-3100, enhancing the probability of success for these developments. Furthermore, Inovio's focus on creating safe and effective outcomes while reducing system costs positions it favorably in the competitive biotechnology landscape.

Bear case

Inovio Pharmaceuticals is currently classified with a Speculative Risk qualifier, reflecting the unpredictability of its future revenues and expenses alongside its non-revenue generating status. The company's focus on developing DNA medicines for oncology and infectious diseases entails significant costs, while the potential for stock price volatility poses risks of substantial upside and downside swings. Overall, these factors contribute to a negative outlook for Inovio Pharmaceuticals' stock, despite its efforts to provide therapeutic options in challenging markets.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.